Wilhelmus Cm Groenhuysen Sells 30,470 Shares of NovoCure (NVCR) Stock

NovoCure (NASDAQ:NVCR) CFO Wilhelmus Cm Groenhuysen sold 30,470 shares of the business’s stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $30.04, for a total value of $915,318.80. Following the completion of the transaction, the chief financial officer now directly owns 201,898 shares in the company, valued at $6,065,015.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Wilhelmus Cm Groenhuysen also recently made the following trade(s):

  • On Friday, May 11th, Wilhelmus Cm Groenhuysen sold 9,393 shares of NovoCure stock. The stock was sold at an average price of $30.01, for a total value of $281,883.93.
  • On Tuesday, May 1st, Wilhelmus Cm Groenhuysen sold 30,470 shares of NovoCure stock. The stock was sold at an average price of $27.58, for a total value of $840,362.60.
  • On Friday, February 23rd, Wilhelmus Cm Groenhuysen sold 13,351 shares of NovoCure stock. The stock was sold at an average price of $19.83, for a total value of $264,750.33.

Shares of NVCR opened at $29.00 on Thursday. The company has a market cap of $2.72 billion, a PE ratio of -41.43 and a beta of 3.07. NovoCure has a 1 year low of $28.65 and a 1 year high of $29.40. The company has a debt-to-equity ratio of 1.41, a quick ratio of 5.87 and a current ratio of 6.32.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, April 26th. The medical equipment provider reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.10). The firm had revenue of $52.13 million for the quarter, compared to analysts’ expectations of $57.13 million. NovoCure had a negative return on equity of 56.70% and a negative net margin of 33.12%. equities analysts forecast that NovoCure will post -0.6 EPS for the current fiscal year.

A number of research firms recently commented on NVCR. BidaskClub raised NovoCure from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 12th. ValuEngine raised NovoCure from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Zacks Investment Research cut NovoCure from a “buy” rating to a “hold” rating in a report on Tuesday, May 1st. Wedbush upped their price objective on NovoCure from $29.00 to $33.00 and gave the stock an “outperform” rating in a report on Friday, April 27th. Finally, Deutsche Bank raised NovoCure from a “hold” rating to a “buy” rating and decreased their price objective for the stock from $23.80 to $19.00 in a report on Thursday, April 19th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $25.20.

Several institutional investors and hedge funds have recently modified their holdings of NVCR. Wells Fargo & Company MN raised its holdings in shares of NovoCure by 44.8% during the 3rd quarter. Wells Fargo & Company MN now owns 66,058 shares of the medical equipment provider’s stock worth $1,312,000 after acquiring an additional 20,439 shares in the last quarter. Frontier Capital Management Co. LLC increased its position in shares of NovoCure by 29.8% during the 4th quarter. Frontier Capital Management Co. LLC now owns 1,081,898 shares of the medical equipment provider’s stock valued at $21,854,000 after purchasing an additional 248,322 shares during the last quarter. Peregrine Capital Management LLC increased its position in shares of NovoCure by 38.0% during the 4th quarter. Peregrine Capital Management LLC now owns 865,671 shares of the medical equipment provider’s stock valued at $17,487,000 after purchasing an additional 238,195 shares during the last quarter. Chicago Equity Partners LLC increased its position in shares of NovoCure by 53.0% during the 4th quarter. Chicago Equity Partners LLC now owns 155,725 shares of the medical equipment provider’s stock valued at $3,146,000 after purchasing an additional 53,930 shares during the last quarter. Finally, Engineers Gate Manager LP increased its position in shares of NovoCure by 202.3% during the 4th quarter. Engineers Gate Manager LP now owns 67,899 shares of the medical equipment provider’s stock valued at $1,372,000 after purchasing an additional 45,438 shares during the last quarter. 42.54% of the stock is currently owned by institutional investors and hedge funds.

NovoCure Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply